Key terms

About DCPH

Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. The company was founded by Peter A. Petillo and Daniel L. Flynn in 2003 and is headquartered in Waltham, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest DCPH news

Apr 22 8:32am ET Piper Sandler Sticks to Their Buy Rating for Deciphera Pharmaceuticals (DCPH) by TipRanks Apr 08 8:40am ET Analysts Have Conflicting Sentiments on These Healthcare Companies: Deciphera Pharmaceuticals (DCPH) and Shockwave Medical (SWAV) by TipRanks Feb 21 6:51am ET Barclays Keeps Their Sell Rating on Deciphera Pharmaceuticals (DCPH) by TipRanks Feb 07 8:40am ET Stifel Nicolaus Remains a Buy on Deciphera Pharmaceuticals (DCPH) by TipRanks Feb 07 8:31am ET Buy Rating Reaffirmed for Deciphera Pharmaceuticals on Strong Q4 Performance and Promising Drug Prospects by TipRanks Feb 07 6:20am ET Wall Street Analysts Are Bullish on Top Healthcare Picks by TipRanks Feb 07 5:19am ET Deciphera Pharmaceuticals (DCPH) Gets a Sell from Barclays by TipRanks Feb 07 12:50am ET Analysts Are Bullish on Top Healthcare Stocks: Deciphera Pharmaceuticals (DCPH), ACADIA Pharmaceuticals (ACAD) by TipRanks Feb 06 12:45pm ET Deciphera Pharmaceuticals: Strong Buy Rating on Robust Financials and Promising Pipeline by TipRanks Feb 06 11:35am ET Deciphera Pharmaceuticals: Sustained Growth and Market Expansion Drive Buy Rating by TipRanks Feb 06 7:08am ET Deciphera sees NDA submission for Vimseltinib in 2Q24 by TipRanks Feb 06 7:08am ET Deciphera sees NDA submission for Vimseltinib in 2Q24 by TipRanks Feb 06 7:04am ET Deciphera reports Q4 EPS (54c), consensus (58c) by TipRanks Jan 22 2:23pm ET Piper Sandler Remains a Buy on Deciphera Pharmaceuticals (DCPH) by TipRanks

No recent press releases are available for DCPH

DCPH Financials

1-year income & revenue

Key terms

DCPH Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

DCPH Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

A bubble tea store operated by Sichuan Baicha Baidao in Shanghai, China, on April 23, 2024.
Raul Ariano/Bloomberg/Getty Images
Is the tea bubble bursting? ChaPanda shares plunge in Hong Kong IPO
People walk past the New York Stock Exchange (NYSE) on April 10, 2024 in New York City.
Spencer Platt/Getty Images
Can markets make a comeback? That depends on tech earnings
People walk past the New York Stock Exchange Thursday, March. 21, 2024.
Yuki Iwamura/AP
Investors are fearful. They shouldn’t be
People walk past the New York Stock Exchange (NYSE) on March 28, 2024 in New York City.
NDZ/STAR MAX/IPx/AP
What stalled this year’s seemingly infallible stock market rally